As­traZeneca-al­lied Ec­co­gene tar­gets ear­ly 2025 Nas­daq IPO with mul­ti­ple NASH can­di­dates

Ec­co­gene, a Boston and Shang­hai biotech work­ing on an oral GLP-1 can­di­date with As­traZeneca, is con­sid­er­ing an ini­tial pub­lic of­fer­ing ear­ly next year, CEO Jingye …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.